Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Call for papersOncology

Call for Papers: Antibody-drug conjugates for cancer treatment: translational and clinical perspectives (BMC Medicine)

BMC Medicine’s collection on antibody-drug conjugates covers ADCs in cancer treatment, from translational work through to clinical use. This guide outlines topic areas consistent with that scope, fit checks for manuscripts and the kinds of contribution likely to interest the editors.

Pubrica InsightsEditorial team, reviewed by a subject specialist
Deadline
7 December 2026
Last checked
10 November 2026
Reading time
5 min
Sources
1
Submit through the official call

Key dates

Manuscript deadline
7 December 2026
Details last checked
10 November 2026
Open the official call

About the journal

Journal
BMC Medicine
Publisher
BMC, part of Springer Nature
Call type
Call for papers
Scope
ADCs in cancer treatment, from translational work through to clinical use.
Guest editors
Listed on the official collection page
Access and fees
Open access; an article processing charge normally applies on acceptance
Originality
Original work, not under review elsewhere; confirm on the official page

Topics consistent with the call

  • Clinical trials of antibody-drug conjugates in solid tumours and haematological cancers
  • Translational studies of target expression, biomarkers and patient selection for ADCs
  • Studies examining resistance mechanisms to antibody-drug conjugate therapy
  • Real-world evidence on ADC effectiveness, toxicity and treatment sequencing
  • Systematic reviews and meta-analyses of ADC efficacy and safety
  • Management of ADC-associated adverse events such as interstitial lung disease

Based on the published scope; the full list of themes is on the official call page.

Is your work a fit? Check before you write

  1. Antibody-drug conjugates are the central focus of the manuscript, whether in translational or clinical research.
  2. The work has clear relevance to cancer treatment decisions or to the development of ADCs towards clinical use.
  3. The design suits BMC Medicine, such as a trial, observational study, systematic review or translational study with clinical implications.
  4. Reporting follows the appropriate guideline, for example CONSORT, STROBE, REMARK or PRISMA.
  5. The manuscript is complete, approved by all co-authors and submitted before 7 December 2026, after confirming accepted article types on the official call page.

Why This Call Is a Priority Now

Antibody-drug conjugates combine the targeting of monoclonal antibodies with the potency of cytotoxic payloads, and several are now part of routine oncology practice. Their expanding use raises practical questions about patient selection, biomarkers, sequencing with other therapies, resistance and the management of distinctive toxicities. A themed collection in a general medical journal brings translational and clinical evidence together, helping oncologists and researchers follow developments across tumour types and giving authors a focused venue that connects laboratory findings with clinical outcomes.

Who Should Submit

Academic backgrounds

  • Medical oncology
  • Haematology
  • Cancer pharmacology
  • Translational cancer biology
  • Clinical trial methodology and biostatistics

Institutions and sectors

  • Comprehensive cancer centres and university hospitals
  • Pharmaceutical and biotechnology companies
  • Cooperative oncology trial groups
  • Academic research institutes

Article types commonly published in BMC Medicine

  • Clinical trials and other interventional studies
  • Observational studies
  • Systematic reviews and meta-analyses
  • Translational and mechanistic research

What the Editors Typically Value

  1. Clinical evidence that clarifies which patients benefit most from a specific ADC.
  2. Translational findings on biomarkers or resistance that have a credible route to clinical application.
  3. Real-world or pooled analyses that address safety signals or treatment sequencing not resolved by pivotal trials.
  4. Methodological work that improves how ADC trials are designed, analysed or reported.

Paper Ideas You Could Develop

Target expression and responseA translational study relating tumour target expression levels to response and survival in patients treated with an ADC.
Sequencing after ADC therapyA multicentre retrospective cohort comparing outcomes of subsequent treatment options after progression on an antibody-drug conjugate.
Pulmonary toxicity meta-analysisA systematic review and meta-analysis of the incidence and severity of interstitial lung disease across ADC trials.

Your Plan to the Deadline

A suggested schedule working back from 7 December 2026. Adjust it to the stage your work has reached.

  1. By 23 Oct 2026

    Open the official collection page and the BMC Medicine submission guidelines; confirm the scope, article types and guest editors.

  2. By 6 Nov 2026

    Write a one-paragraph statement of your research question, design and the contribution your paper makes to the collection.

  3. By 16 Nov 2026

    Complete the analysis and agree the key findings, figures and tables with your co-authors.

  4. By 27 Nov 2026

    Draft the full manuscript to the BMC Medicine article type and the relevant reporting guideline.

  5. By 2 Dec 2026

    Circulate the draft to co-authors and an independent reader; revise for clarity, accuracy and completeness.

  6. By 5 Dec 2026

    Complete final checks: formatting, references, declarations, data availability statement and cover letter.

  7. By 7 Dec 2026

    Submit through the journal’s online system, selecting the collection, after re-checking the official call page.

What you gain from publishing here

  • Publication in BMC Medicine, reaching readers working on this topic.
  • A themed collection that groups your paper with related work.
  • Editorial and peer feedback that can strengthen the work, whatever the decision.
  • A peer-reviewed output for your CV, thesis or grant reporting.

What happens after you submit

  1. Submission: upload through the BMC Medicine online system and select the collection.
  2. Editorial screening: the editors check fit with the collection; papers outside its scope may be returned without review.
  3. Peer review: suitable papers are sent to reviewers under the journal’s review model.
  4. Revision and decision: respond to each reviewer comment and keep a record of the changes.
  5. Production: accepted papers move to proofs and open access publication, with the article processing charge set out by the publisher.

What the Collection Is Looking For

The collection seeks research that advances the understanding and use of antibody-drug conjugates in cancer care, spanning translational investigation and clinical application. In keeping with BMC Medicine’s remit, it is likely to favour studies with clear clinical relevance: trials, robust observational analyses, systematic reviews and translational work with a defined path to patient benefit. Transparent reporting of efficacy, toxicity and patient selection will strengthen a submission.

Read the call itselfThis guide summarises the call. Open the official collection page before you plan a submission, and record the date you checked it and the guest editors listed.Open the official call

Expert help

How Pubrica Can Help With This Submission

Pubrica’s subject specialists can review, write, edit, format and prepare your manuscript for this call, planned back from the deadline. You remain the author of your work.

Original research article writingManuscript writing from your data, structured to the journal’s article type and reporting guideline. Biostatistics and statistical programmingStatistical analysis plans, analysis, simulation code and statistical review of results. Systematic reviewProtocol, screening, data extraction and risk-of-bias assessment for review articles. Journal formattingFormatting of the manuscript, references, figures and tables to the journal’s guidelines. Cover letterA cover letter that explains how the manuscript fits the collection and the journal’s scope. Journal submissionPreparation of submission files and completion of the journal’s online submission system.
Go to the official call

FAQs

Questions Authors Ask

The published deadline is 7 December 2026. Collections can close early or be extended, so confirm the date on the official call page before you plan your submission.

The guest editors are listed on the official collection page. Check their research interests, as they help to judge whether your manuscript fits the collection.

Preclinical work may fit if it has a clear translational rationale and implications for clinical development, given the collection’s translational scope. BMC Medicine is a general medical journal, so purely laboratory studies without clinical relevance may be less suited; authors should confirm the accepted article types on the official call page.

BMC journals publish articles open access, and an article processing charge normally applies on acceptance. Check the journal’s fees and funding page, and whether your institution has an agreement that covers the charge, before you submit.

Sources

  1. BMC Medicine. (2026). Antibody-drug conjugates for cancer treatment: translational and clinical perspectives [Collection call for papers]. BMC, part of Springer Nature. Retrieved 10 November 2026, from https://link.springer.com/collections/jjicaadfga

How to cite this page

Pubrica Insights. (2026). Call for Papers: Antibody-drug conjugates for cancer treatment: translational and clinical perspectives (BMC Medicine). Pubrica. https://pubrica.com/insights/calls-and-conferences/antibody-drug-conjugates-for-cancer-treatment-translational-and-clinic/

  • Antibody-drug conjugates
  • Oncology
  • Targeted therapy
  • Translational research
  • Clinical trials

Other Open Calls

Closes 17 November 2026Organoids: connecting molecular insights and clinical practiceBMC Medicine Closes 30 November 2026New research in autismBMC Medicine Closes 11 January 2027Ultra-processed food and health: evidence, mechanisms, and policy implicationsBMC Medicine

All calls and conferencesPre-submission peer reviewAll Insights

Antibody-drug conjugates for cancer treatment: translational and clinical perspectives (BMC Medicine)Deadline 7 December 2026

Official call
Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.